

ME THERAPEUTICS HOLDINGS INC.

Management's Discussion and Analysis for the year ended August 31, 2024 (including Subsequent Events to November 26, 2024)

The following discussion and analysis of the results of operations and financial condition of ME Therapeutics Holdings Inc. (formerly Metx Research Corp.) ("METX" or the "Company") as at and for the year ended August 31, 2024 should be read in conjunction with the audited consolidated financial statements and related notes as at and for the year ended August 31, 2024, which are prepared in accordance with the IFRS Accounting Standards ("IFRS").

On March 9, 2023, the Company completed the acquisition of all of the issued and outstanding securities in the capital of ME Therapeutics Inc. ("METI"), a private company incorporated on September 16, 2014 under the laws of the Province of British Columbia, in exchange for the issuance of an aggregate of 14,999,994 common shares in the capital of the Company to the shareholders of METI pursuant to the terms of an Securities Exchange Agreement (the "Agreement") dated October 4, 2022 (and as amended on October 12, 2022, and March 7, 2023) between the Company and METI (collectively, the "Transaction"), which received shareholder approval. Further, the Company issued 121,670 replacement stock options, exercisable at a price of \$0.40 and with an expiry of five years from the date of grant. The Transaction was accounted for as a reverse acquisition (see note 3 to the audited consolidated financial statements for additional details).

Management is responsible for the preparation and integrity of the financial statements, including the maintenance of appropriate information systems, procedures and internal controls. Management is also responsible for ensuring that information disclosed externally, including the financial statements and Management Discussion and Analysis ("MD&A"), is complete and reliable.

The consolidated financial statements, MD&A and all other continuous disclosure documents are filed with Canadian securities regulators and are available for review under the Company's profile at www.sedar.com.

FORWARD-LOOKING STATEMENTS

Except for statements of historical fact, certain information contained herein constitutes forward-looking statements. Forward-looking statements are usually identified by use of certain terminology, including "will", "believes", "may", "expects", "should", "seeks", "anticipates" or "intends" or by discussions of strategy or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or achievements to be materially different from any future results or achievements expressed or implied by such forward-looking statements.

Forward-looking statements are statements that are not historical facts, and include but are not limited to: estimates and their underlying assumptions; statements regarding plans; objectives and expectations with respect to the effectiveness of the Company's business model; future operations, products and services; the impact of regulatory initiatives on the Company's operations; the size of and opportunities related to the market for the Company's products; general industry and macroeconomic growth rates; expectations related to possible joint or strategic ventures; and statements regarding future performance.

Forward-looking statements used in this MD&A are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond the control of the Company. If risks or uncertainties materialize, or if underlying assumptions prove incorrect, the actual results may vary materially from those expected, estimated or projected. The Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws.

There can be no assurance that such statements will prove to be accurate, and future events and actual results could differ materially from those anticipated in such statements. Given these uncertainties, the reader of the information included herein is cautioned not to place undue reliance on such forward-looking statements.

DESCRIPTION OF BUSINESS

The Company (through METI) is a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology ("IO"). Since its incorporation on September 16, 2014, METI has primarily been conducting research in IO. The strategy of the Company is to develop drug candidates that can increase the efficacy of current IO drugs by targeting suppressive myeloid cells which are known to hinder the effectiveness of current IO treatments. The Company's lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. This antibody drug candidate is currently being developed to treat colorectal cancer; however, the Company believes it has the potential to be used in several distinct cancer types.

In addition to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumour environment. The active component of this prodrug candidate has been shown to interfere with several key pathways involved in immune suppression and cancer growth. Since the prodrug targets the immune system rather than the cancer cells, the Company believes it may be useful for several distinct cancer types. The Company has recently initiated design and testing of two new mRNA-based cancer therapeutic drug candidates. This program is being done in collaboration with a partner with extensive experience in lipid nanoparticle (LNP) delivery of mRNA therapeutics. Our lead mRNA candidates target a known mechanism of immune stimulation which has been well characterized and is a potential avenue towards enhancing anti-tumour immunity. The Company intends to continue to discover and develop new drug candidates targeting suppressive myeloid cells that may be beneficial for the treatment of cancer and advance those drug candidates towards human clinical studies.

OVERALL PERFORMANCE

As at August 31, 2024, the Company has no debt and working capital of \$1,475,569 (including related party payables of \$16,780).

Prior to completing the Transaction with METI, METX completed two financings as follows:

- On October 21, 2022, METX completed a private placement whereby a total of 1,160,000 units were sold at \$0.25 per unit for gross proceeds of \$290,000. Each unit is comprised of one common share and one share purchase warrant, with each warrant being exercisable into an additional common share at a price of \$0.40 for a period of three years expiring October 21, 2025.
- On March 1, 2023, METX completed a private placement whereby a total of 694,443 units were sold at \$0.45 per unit for gross proceeds of \$312,500. Each unit is comprised of one common share and one half of one share purchase warrant, with each whole warrant being exercisable into an additional common share at a price of \$1.00 for a period of three years expiring March 1, 2026.

During the year ended August 31, 2024, METX completed the following financing:

- On March 6, 2024, the Company completed a unit offering whereby a total of 1,555,000 units were issued at a price of \$1.00 per unit for gross proceeds of \$1,555,000 (the “March 2024 Financing”). Each unit is comprised of one common share and one warrant exercisable at a price of \$1.50 for a period of two years. The warrants are subject to an acceleration clause whereby if the daily trading price of the Company’s common shares equals or exceeds \$2.00 for a period of ten consecutive trading days, the Company may accelerate the warrants, which will then expire on the 30th day after the date on which the news release is disseminated. No value was allocated to the warrant component of the units sold.

The Company does not have revenues and has recurring operating losses from incorporation. This indicates the existence of a material uncertainty that may cast significant doubt about the Company’s ability to continue as a going concern. Management intends to finance operating costs with equity financings, or loans from related parties. If the Company is unable to continue as a going concern, the net realizable value of its assets may be materially less than the amounts on its consolidated statements of financial position.

SELECTED ANNUAL INFORMATION

The financial information presented below has been derived from the METI audited financial statements (as the acquirer in the reverse acquisition) for the years ended August 31, 2024, 2023, and 2022.

	August 31, 2024	August 31, 2023	August 31, 2022
Revenues	Nil	Nil	Nil
Net Loss	(\$1,294,635)	(\$6,520,390)	(\$145,784)
Net Loss per Share - Basic and Diluted	(\$0.05)	(\$0.45)	(\$0.02)
Total Assets	\$1,538,645	\$671,861	\$102,462
Total Long-term Financial Liabilities	Nil	Nil	\$60,000
Cash Dividends Declared per Share	Nil	Nil	Nil

Total assets increased from 2023 to 2024 mainly due to an increase in current assets (cash) associated with completion of the March 2024 Financing. All other asset categories remained consistent between years.

Total assets increased from 2022 to 2023 mainly due to an increase in current assets associated with completion of the Transaction, as well as additional cash raised through the common share financing completed in August 2023. All other asset categories remained consistent between years.

During the year ended August 31, 2024, METI expensed research-related costs of approximately \$312,000. METI had entered into a Material Transfer and Collaborative Research Agreement (the “CBA Agreement”) with Integrated Nanotherapeutics Inc. (“INT”) whereby INT had undertaken a defined research plan on behalf of METI.

Furthermore, the Company continued their efforts on the prodrug candidate development program including the CBA Agreement, discussed above, as well as animal efficacy testing of the prodrug candidates at BC Cancer Agency and Crown Biosciences Inc. The Company also initiated studies testing the safety of our lead antibody candidate in non-human primates at our contract research partner, Bioduro-Sundia.

During the year ended August 31, 2023, METI expensed research-related costs of approximately \$27,000. The majority of these costs, approximating \$25,000, were associated with the CBA Agreement.

During the year ended August 31, 2022, METI expensed research-related costs of approximately \$55,000. The majority of these costs, approximating \$50,000, were associated with the CBA Agreement.

SUMMARY OF QUARTERLY RESULTS

The following table shows the results for the last quarter compared to those from the previous seven quarters.

Period Ending	Revenues	Net Loss	Net Loss per Share
August 31, 2024	Nil	(\$312,040)	(\$0.01)
May 31, 2024	Nil	(\$495,991)	(\$0.02)
February 29, 2024	Nil	(\$143,491)	(\$0.01)
November 30, 2023	Nil	(\$343,113)	(\$0.01)
August 31, 2023	Nil	(\$384,331)	(\$0.02)
May 31, 2023	Nil	(\$6,057,545)	(\$0.28)
February 28, 2023	Nil	(\$38,061)	(\$0.01)
November 30, 2022	Nil	(\$40,453)	(\$0.01)

RESULTS OF OPERATIONS AND THIRD QUARTER RESULTS

The Company (through METI) is a research-stage company and has no operating revenues. Most of its expenditures are research related and are not capitalized for accounting purposes.

The net loss for the year ended August 31, 2024 compared to the net loss for the year ended August 31, 2023 decreased by approximately \$5,226,000. This was caused predominantly by a decrease in transaction expense (associated with the Transaction) of approximately \$5,567,000, a decrease in professional fees of approximately \$132,000, and an increase in Government assistance of approximately \$47,000.

This overall decrease was partially offset by an increase in research costs of approximately \$285,000, an increase in share-based compensation expense of approximately \$103,000, an increase in general and administrative costs of approximately \$86,000, and an increase in consulting fees of approximately \$54,000.

Current year research costs were largely associated with the Company's prodrug candidate development program including the CBA Agreement, as well as animal efficacy testing of the prodrug candidates at BC Cancer Agency and Crown Biosciences Inc. The Company also initiated studies testing the safety of our lead antibody candidate in non-human primates at our contract research partner, Bioduro-Sundia.

Research costs increased as the Company contracted out and completed research studies on its lead antibody drug candidate and prodrug candidates. The decrease in professional fees was mainly due to the completion of the Transaction and public listing which reduced legal fees associated with those transactions. Consulting fees were increased due to a change in compensation for the CEO who is now being paid a monthly consulting fee of \$10,000 for his services. We expect consulting fees to increase in F2025 with the addition of two new clinical consultants hired to advance the Company's lead antibody candidate towards a first in human clinical trial.

Finally, the increase in general and administrative expenses can be attributed to an increase in the business development activities of the Company, including the attendance at investor conferences, geared towards enhancing investor awareness.

All other amounts remained consistent between years.

FOURTH QUARTER RESULTS

The net loss for the three months ended August 31, 2024 compared to the net loss for the three months ended August 31, 2023 decreased by approximately \$72,000. This was caused, by the most part, by a decrease in share-based compensation expense of approximately \$77,000, and a decrease in professional fees of approximately \$77,000 (largely associated with legal fees incurred in connection with the Transaction and subsequent listing). This overall decrease was partially offset by an increase in research costs of approximately \$45,000, and an increase in consulting fees of approximately \$31,000.

All other amounts remained consistent between periods.

LIQUIDITY AND CAPITAL RESOURCES

1. Working Capital

Working capital totaled \$1,475,569 as at August 31, 2024 compared to a working capital of \$523,191 as at August 31, 2023. The increase in working capital was directly associated with the March 2024 Financing, offset by working capital and general operating costs incurred.

2. Financings

On January 13, 2022, the Company completed a private placement whereby a total of 2,250,000 units were sold at \$0.02 per unit for gross proceeds of \$45,000. Each unit is comprised of one common share and one share purchase warrant, with each warrant being exercisable into an additional common share at a price of \$0.20 for a period of three years expiring January 13, 2025.

On January 26, 2022, the Company completed a private placement whereby a total of 4,200,000 units were sold at \$0.05 per unit for gross proceeds of \$210,000. Each unit is comprised of one common share and one share purchase warrant, with each warrant being exercisable into an additional common share at a price of \$0.25 for a period of three years expiring January 26, 2025.

On October 21, 2022, the Company completed a private placement whereby a total of 1,160,000 units were sold at \$0.25 per unit for gross proceeds of \$290,000. Each unit is comprised of one common share and one share purchase warrant, with each warrant being exercisable into an additional common share at a price of \$0.40 for a period of three years expiring October 21, 2025.

On March 1, 2023, the Company completed a private placement whereby a total of 694,443 units were sold at \$0.45 per unit for gross proceeds of \$312,500. Each unit is comprised of one common share and one half of one share purchase warrant, with each whole warrant being exercisable into an additional common share at a price of \$1.00 for a period of three years expiring March 1, 2026.

Between January 27, 2022 and February 10, 2022, METI closed a convertible debenture offering whereby gross proceeds of \$140,000 was raised. Each debenture consisted of an interest-free, unsecured convertible debenture with a maturity of one year from the date of issuance. At the option of the holder, the debentures were convertible into common shares of METI at a conversion price of \$0.01 (amended to \$0.03 in connection with the Transaction). The debentures were automatically converted immediately preceding completion of the Transaction.

On August 9, 2023, the Company completed the first tranche of a private placement whereby a total of 212,222 common shares were sold at \$0.45 per share for gross proceeds of \$95,500.

On August 18, 2023, the Company completed the second tranche of a private placement whereby a total of 44,500 common shares were sold at \$0.45 per share for gross proceeds of \$20,025.

On March 6, 2024, the Company completed a unit offering whereby a total of 1,555,000 units were issued at a price of \$1.00 per unit for gross proceeds of \$1,555,000. Each unit is comprised of one common share and one warrant exercisable at a price of \$1.50 for a period of two years. The warrants are subject to an acceleration clause whereby if the daily trading price of the Company's common shares equals or exceeds \$2.00 for a period of ten consecutive trading days, the Company may accelerate the warrants, which will then expire on the 30th day after the date on which the news release is disseminated.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not utilize off-balance sheet arrangements.

TRANSACTIONS WITH RELATED PARTIES

Key management personnel are the persons responsible for the planning, directing, and controlling the activities of the Company and includes both executive and non-executive Directors, and entities controlled by such persons. The Company considers all Directors and Officers of the Company to be key management personnel.

During the year ended August 31, 2024, the Company paid or accrued \$50,000 in consulting fees to a company controlled by the Company's CEO.

During the year ended August 31, 2024, the Company paid or accrued \$37,500 in professional fees to DBM CPA Inc. ("DBM"), a company in which the Company's CFO is a principal and exerts significant influence.

During the year ended August 31, 2023, the Company granted a total of 1,925,000 stock options to Directors and Officers, having a fair value on issuance of \$637,291.

As at August 31, 2024, \$12,580 is owing to the Company's CEO, and \$4,200 is owing to DBM.

RISKS AND UNCERTAINTIES

In conducting its business, the Company (through METI) faces a number of risks and uncertainties related to the biotechnology industry. Some of these risk factors include risks associated with biotechnology, the requirement and ability to raise additional capital through future financings and price volatility of the Company's securities (subsequent to listing).

History of losses and access to financing

The Company will be a preclinical stage company with a history of losses and the Company cannot assure profitability.

The Company does not have a source of operating cashflow and is dependent on future financings to support the development of its drug products. If the Company sustains losses over an extended period of time without any further financing support, it may be unable to continue its business.

Access to materials/supplies

An inability to obtain raw materials or product supply could have a material adverse impact on the Company's business, financial condition and results of operations. Currently, the Company relies on third party suppliers and manufacturers for its drug products and there may be situations where raw materials become unavailable due to unforeseen circumstances.

Reliance on key management

The Company is highly dependent on key personnel. The Company may not be able to attract and retain personnel on acceptable terms given the intense competition for such personnel among high technology enterprises, including biotechnology, and healthcare companies, universities and non-profit research institutions. Any loss of personnel or inability to recruit new personnel will have a material adverse impact on the Company.

Intellectual property

The Company's ability to compete may depend on the superiority, uniqueness and value of any intellectual property and technology that it may develop or license. To the extent the Company is able to do so, to protect any proprietary rights of the Company, the Company intends to rely on a combination of patent, trademark, copyright and trade secret laws, confidentiality agreements with its employees and third parties, and protective contractual provisions. Despite these efforts, any of the following occurrences may reduce the value of any of the Company's intellectual property: (i) issued patents, trademarks and copyright registrations may not provide the Company with competitive advantages; (ii) the Company's efforts to protect the current intellectual property rights of ME Therapeutics may not be effective in preventing misappropriation of any its products or intellectual property rights by third parties; (iii) the Company's efforts may not prevent the development and design by others of products or marketing strategies similar to or competitive with, or superior to those the Company develops; (iv) another party may assert a blocking patent and the Company would need to either obtain a license or design around the patent in order to continue to offer the contested feature or service in its products; (v) another party may assert an interest in the Company's or ME Therapeutics' patents, patent applications or other intellectual property rights; or (vi) the expiration of patent or other intellectual property protections for any

assets owned or licensed by the Company or ME Therapeutics could result in significant competition, potentially at any time and without notice, resulting in a significant reduction in sales. The effect of the loss of these protections on the Company and its financial results will depend, among other things, upon the nature of the market and the position of the Company's products in the market from time to time, the growth of the market, the complexities and economics of manufacturing a competitive product and regulatory approval requirements but the impact could be material and adverse.

The Company's intellectual property rights may provide only limited protection for its technology and may not be sufficient to provide the Company with a competitive advantage. Despite the Company's efforts to protect its intellectual property or proprietary rights, unauthorized parties may attempt to infringe its intellectual property rights, including by copying aspects of our technology or obtaining and using information that the Company considers proprietary or confidential. Policing the Company's intellectual property and proprietary rights is difficult and may not always be effective.

Reliance on contractors

The Company relies on the expertise and availability of contract research organizations to carry out preclinical testing. In the event that a contract research organization is unavailable or unwilling to carry out the studies necessary for the development of the Company's drug products, this will have an adverse effect on the Company's business.

The Company relies on Integrated Nanotherapeutics to carry out the design and manufacture of its lead prodrug candidate. Any negative impacts on the ability of Integrated Nanotherapeutics to continue this work would materially impact the Company's prodrug development program.

Stage of development

The Company's drug products are the preclinical stage of development and there is no way to know if any of the drug products will demonstrate acceptable efficacy in preclinical testing which would prevent the further development of those drug products and have an adverse effect on the Company.

Regulatory risks

The Company will rely on regulatory approval from various Government agencies for future clinical development of its drug products. If any regulatory agency denies a clinical trial applications for a reason which cannot be remedied, this will have a material adverse effect on the Company.

CRITICAL ACCOUNTING ESTIMATES AND FINANCIAL INSTRUMENTS

The Company prepares its financial statements in conformity with IFRS. The Company lists its material accounting policy information and its financial instruments in Notes 2 and 11, respectively, to its annual audited consolidated financial statements for the year ended August 31, 2024. Of the accounting policies, the Company considers the following policy to be the most critical to the reader's full understanding and evaluation of the Company's reported financial results.

Research costs

Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss (research) as incurred. Investment tax credits related to current expenditures are included in the determination of profit or loss as the expenditures are incurred when there is reasonable assurance they will be realized. The Company expenses legal fees incurred on application costs relating to its pending patents as incurred.

MANAGEMENT AND BOARD OF DIRECTORS

In connection with the completion of the Transaction on March 9, 2023, the Company's Board of Directors is comprised of the Board members of METI going forward, with one Director being appointed by METX. Further, on June 7, 2023, the Company appointed Karim Nanji to the Board of Directors. See below for complete listing.

The Company's Officers are also those of METI, following completion of the Transaction. See below for complete listing.

There were no other changes to management during the year ended August 31, 2024.

INVESTOR RELATIONS

All investor relations activities are performed by Company management.

GOVERNMENT ASSISTANCE

Scientific Research and Experimental Development ("SRED")

SRED is a federal tax incentive program designed to encourage Canadian businesses of all sizes and in all sectors to conduct research and development in Canada.

During the year ended August 31, 2024, the Company accrued \$nil in Government assistance proceeds associated with the SRED program, which is presented within profit or loss as Government assistance.

As at August 31, 2022, METI had accrued \$17,000 in Government assistance proceeds associated with the SRED program. These funds were received during the year ended August 31, 2023.

Canadian Emergency Business Account (“CEBA”)

During the year ended August 31, 2020, METI qualified for a Government-guaranteed line of credit (Government loan) of \$40,000 which was free of interest and to be repaid by December 31, 2023, at which time a 25% balance forgiveness (\$10,000) will apply if the loan is repaid by such date.

During the year ended August 31, 2021, METI qualified for an additional Government-guaranteed line of credit (Government loan) of \$20,000 which was free of interest and to be repaid by December 31, 2023, at which time a 50% balance forgiveness (\$10,000) will apply if the loan is repaid by such date.

During the year ended August 31, 2024, all amounts were repaid.

NRC Industrial Research Assistance Program (“NRC-IRAP”)

NRC-IRAP is a federal research assistance program designed to provide funding assistance to small and medium-sized businesses to conduct research and development in Canada.

During the year ended August 31, 2024, the Company received \$46,782 in Government assistance proceeds associated with the NRC-IRAP program.

REVERSE ACQUISITION

As described in note 3 of the audited consolidated financial statements, on March 9, 2023, the Company (METX) and METI completed a Transaction which constituted a reverse acquisition, with METI shareholders receiving 1.395 shares of METX for every share of METI held. This resulted in METI shareholders controlling approximately 64.4% of the issued and outstanding shares of the Company.

The Transaction resulted in the shareholders of METI obtaining control of the combined entity by obtaining control of the voting rights, governance, and management decision-making processes, and the resulting power to govern the financial and operating policies of the combined entities.

The Transaction constitutes a reverse acquisition (“RTO”) of METX by METI and has been accounted for as a reverse acquisition transaction in accordance with the guidance provided in IFRS 2, Share-based Payments and IFRS 3, Business Combinations. As METX did not qualify as a business according to the definition in IFRS 3, the RTO does not constitute a business combination; rather it is treated as an issuance of common shares by METI for the net assets of METX and METX’s public listing, with METI as the continuing entity. Accordingly, no goodwill or intangible assets were recorded with respect to the Transaction as it does not constitute a business.

For accounting purposes, METI is treated as the accounting parent company (legal subsidiary) and METX as the accounting subsidiary (legal parent) in these financial statements. As METI was deemed to be the acquirer for accounting purposes, its assets, liabilities and operations since incorporation are included in the consolidated financial statements at their historical carrying values. METX’s results of operations have been included from March 9, 2023.

On closing of the Transaction, METI's nominees will comprise the entirety of the Board of the combined entity with the exception of one Director being appointed by METX. Further, METI's Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") remain as CEO and CFO of the combined entity.

SUBSEQUENT EVENTS

On September 18, 2024, the Company announced the start of efficacy testing of the first two mRNA formulations from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics").

On October 1, 2024, the Company entered into a Sublease Agreement with an arm's length party for new lab and office space in Vancouver. The new space will allow the Company to explore earlier stage drug discovery opportunities to enhance its drug pipeline. The Company expects to continue hiring new scientific research staff in 2025 to design and carry out its research and development activities in its new facilities.

On October 22, 2024, the Company announced that it had initiated the development of a cell line for future good manufacturing practices (GMP) production of h1B11-12 with an experienced partner organization. This work is anticipated to be completed in the second half of 2025. Concurrently, the Company is working with its advisors to choose an appropriate patient population and trial design for its potential clinical trial to be able to conduct any potential supporting nonclinical studies that may be required.

On October 25, 2024, the Company announced the addition of Karim Lalji as Chief Business Officer. This addition was made to help the Company with strategic business decisions including the positioning of its current assets as well as exploring potential in-licensing activities. In regard to the latter, the Company is actively exploring in-licensing of potential assets for its pipeline as well as other strategic business opportunities.

SHARE CAPITAL

The authorized share capital of the Company consists of an unlimited number of common shares without par value and an unlimited number of preferred shares without par value. All issued shares are fully paid. From incorporation to August 31, 2024, no preferred shares have been issued.

On completion of a public listing, it is anticipated that 18,477,772 common shares will be subject to escrow provisions and will have different (and in some cases multiple) escrow release schedules applied. These shares will be released from escrow as follows: (a) an aggregate of 2,727,778 shares will be released over a period of 36 months from the listing date with 10% being released on the listing date and 15% being released every 6 months thereafter (the "NP 46-201 Escrow"), (b) an aggregate of 750,000 will be released from escrow on the date that is 6 months from listing, (c) an aggregate of 2,474,565 shares will be released over 27 months from listing with 10% released on listing, 30% released 9 months from listing, 30% released 18 months from listing and the remaining shares released 27 months from listing (the "Target Voluntary Escrow"); and (d) an aggregate of 12,525,429 shares are subject to both NP 46-201 Escrow and the Target Voluntary Escrow and released over a period of 36 months from listing with 10% released on listing, 15% released 9 months from listing, 15% released 12 months from listing, 15% released 18 months

from listing, 15% released 24 months from listing, 15% released 30 months from listing, and the remaining shares released 36 months from listing.

As at November 26, 2024, there are 25,189,494 common shares outstanding.

Stock Options

As at November 26, 2024, the Company has the following stock options outstanding:

Options outstanding #	Options exercisable #	Exercise price \$	Expiry date
2,175,000	2,175,000	0.45	March 31, 2026
250,000	250,000	0.45	June 7, 2026
250,000	187,500	3.51	April 8, 2027
121,670	121,670	0.40	March 9, 2028
2,796,670	2,734,170		

Warrants

As at November 26, 2024, the Company has the following warrants outstanding:

Warrants outstanding #	Warrants exercisable #	Exercise price \$	Expiry date
1,000,000	1,000,000	0.20	January 13, 2025
3,400,000	3,400,000	0.25	January 26, 2025
660,000	660,000	0.40	October 21, 2025
347,220	347,220	1.00	March 1, 2026
1,555,000	1,555,000	1.50	March 6, 2026
1,250,000	1,250,000	0.20	January 13, 2027
800,000	800,000	0.25	January 26, 2027
500,000	500,000	0.40	October 21, 2027
9,512,220	9,512,220		

ME THERAPEUTICS HOLDINGS INC.

177 Robson Street

Vancouver, B.C. V6B 0N3

Web Site: www.metherapeutics.com

CORPORATE INFORMATION

Salim Dhanji, West Vancouver, B.C. **President, Chief Executive Officer, Director**

John Priatel, Vancouver, B.C. **Director**

Kenneth Harder, Vancouver, B.C. **Director**

Karim Nanji, Vancouver, B.C. **Director**

Quinn Martin, Port Moody, B.C. **Chief Financial Officer**

Jamil Kassam, Vancouver, B.C. **Corporate Secretary**

Auditors

Davidson & Company LLP

1200 – 609 Granville Street

Vancouver, B.C. V7Y 1G6